&w=3840&q=100)
India, US to give preferential market access to businesses, says Goyal
India and the US desire to give preferential market access to each other's businesses and teams of both the countries are working together on the proposed bilateral trade agreement, Commerce Minister Piyush Goyal has said.
In February, US President Donald J Trump and Prime Minister of India Narendra Modi announced plans to negotiate the first tranche or phase of a mutually beneficial, multi-sector Bilateral Trade Agreement (BTA) by fall (September-October) of 2025. It is aimed at more than doubling the bilateral trade to USD 500 billion by 2030 from the current level of USD 191 billion.
"Both countries are committed to work together, both countries desire to give preferential access to each other's businesses and we are working towards the bilateral trade agreement," Goyal told reporters here.
Goyal is here on an official visit to hold talks with French leaders and business representatives to boost trade and investments.
When asked about an announcement of Trump to double tariffs on steel and aluminium to 50 per cent, he also said that the two countries will continue to work together to resolve all these issues bilaterally.
"Let us wait and watch ...both the US and India share good relations and we will continue to work together to resolve all these issues bilaterally," he said.
Trade experts have stated that the further increase in the import duty by the Trump administration would impact Indian exporters, particularly those engaged in value-added and finished steel products and auto-components.
On May 30, Trump announced that he would double the existing 25 per cent tariffs on steel and aluminium imports from June 4.
Trump originally invoked this provision in 2018 to set the 25 per cent tariff on steel and 10 per cent on aluminium. He raised tariffs on aluminium to 25 per cent in February 2025.
In 2024-25, India exported USD 4.56 billion worth of iron, steel, and aluminium products to the US, with key categories, including USD 587.5 million in iron and steel, USD 3.1 billion in articles of iron or steel, and USD 860 million in aluminium and related articles.
India has already issued a formal notice at the World Trade Organization (WTO), reserving its rights to impose retaliatory tariffs on US goods in response to the earlier steel tariffs.
A team of US officials is visiting India this week for discussions on the proposed interim trade agreement between the two countries.
The visit gains importance as India and the US are likely to agree on an interim trade agreement by the end of June, with New Delhi pushing for full exemption from the 26 per cent reciprocal tariff on domestic goods.
India's chief negotiator, Special Secretary in the Department of Commerce Rajesh Agrawal, last month had concluded his four-day visit to Washington.
He held talks with his US counterpart on the proposed agreement.
Goyal too was in Washington to give an impetus to trade talks.
There is a possibility that both sides agree on an interim trade deal before the first tranche.
The US remained India's largest trading partner for the fourth consecutive year in 2024-25, with bilateral trade valued at USD 131.84 billion. The US accounts for about 18 per cent of India's total goods exports, 6.22 per cent in imports, and 10.73 per cent in the country's total merchandise trade.
Talking about India's free trade pact with four-European nation bloc EFTA, Goyal said USD 100 billion FDI (foreign direct investment) commitment under the agreement does not include money coming into stock market through FIIs.
"This is solid FDI coming into the country... This USD 100 billion of FDI comes with technologies... It will (also) catalyse nearly USD 500 billion of investments roughly.
"With this investment, the whole ecosystem gets created, hotels come up, infrastructure comes up, power and water is utilised. The whole ecosystem will add much more to the economy. So it's a massive investments that we are looking coming through this EFTA agreement," he added.
The implementation process of this pact is progressing fast and is expected to come into force before the end of this year.
The two sides signed the Trade and Economic Partnership Agreement (TEPA) on March 10, 2024. Under the pact, India has received an investment commitment of USD 100 billion in 15 years from the grouping while allowing several products such as Swiss watches, chocolates and cut and polished diamonds at lower or zero duties.
The European Free Trade Association (EFTA) members are Iceland, Liechtenstein, Norway, and Switzerland.
When asked if India would have similar arrangement in the proposed trade pact with the 27-nation bloc EU, he said: "The member countries are large investors in india, so we may not go that ground in our FTA with EU.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Economic Times
16 minutes ago
- Economic Times
Carlyle group exits Indegene; sells 10.2% stake for Rs 1,447 crore
Global investment firm Carlyle group on Wednesday exited Indegene by divesting its entire 10.2 per cent stake in digital healthcare services for Rs 1,447 crore through open market transactions. ADVERTISEMENT According to the bulk deal data available on the NSE, US-based Carlyle group, through its arm CA Dawn Investments, sold more than 2.44 crore shares, amounting to a 10.20 per cent stake in Indegene. The shares were offloaded in the price range of Rs 591.02-591.84 apiece, taking the combined transaction value to Rs 1,447.17 crore. Meanwhile, Premji Invest's affiliate PI Opportunities AIF V, Capital group, Societe Generale, Luxembourg-based Eastbridge Group and Abakkus Asset Manager cumulatively bought 1.06 crore shares or 4.42 per cent stake in Indegene for Rs 627 crore. The shares were picked up in the price range of Rs 591-591.48 apiece, taking the aggregate deal value to Rs 626.85 crore. Details of the other buyers of Indegene's shares could not be ascertained on the National Stock Exchange (NSE). ADVERTISEMENT Shares of Indegene declined 4.07 per cent to close at Rs 594.50 per piece on the NSE. PE firm Carlyle group's clocked an impressive 31 per cent internal rate of return over a four-year period. This highly profitable divestment marks a pivotal moment, underscoring the immense potential of India's digital healthcare sector. ADVERTISEMENT In April 2021, Carlyle invested USD 122 million (Rs 917 crore) in Indegene by acquiring 45.5 million shares at Rs 201 each on the stock exchanges. Carlyle executed a phased exit as Indegene scaled its global operations and went public in May 2024. The shares were sold by the PE firm at Rs 452 apiece during the initial public offering, at Rs 618 per share in December 2024, and the final tranche at about Rs 591 each in June 2025, enabling Carlyle to secure significant returns amidst varying market conditions. (You can now subscribe to our ETMarkets WhatsApp channel)


Time of India
18 minutes ago
- Time of India
Carlyle group exits Indegene; sells 10.2% stake for Rs 1,447 crore
Global investment firm Carlyle group on Wednesday exited Indegene by divesting its entire 10.2 per cent stake in digital healthcare services for Rs 1,447 crore through open market transactions. According to the bulk deal data available on the NSE, US-based Carlyle group, through its arm CA Dawn Investments, sold more than 2.44 crore shares , amounting to a 10.20 per cent stake in Indegene. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like コンピュータでゲームをするのが好きなら、この新しいアドベンチャーゲームは必ずプレイすべきです。 アドベンチャーゲーム ゲームをプレイ Undo The shares were offloaded in the price range of Rs 591.02-591.84 apiece, taking the combined transaction value to Rs 1,447.17 crore. Play Video Pause Skip Backward Skip Forward Unmute Current Time 0:00 / Duration 0:00 Loaded : 0.00% 0:00 Stream Type LIVE Seek to live, currently behind live LIVE Remaining Time - 0:00 1x Playback Rate Chapters Chapters Descriptions descriptions off , selected Captions captions settings , opens captions settings dialog captions off , selected Audio Track default , selected Picture-in-Picture Fullscreen This is a modal window. Beginning of dialog window. Escape will cancel and close the window. Text Color White Black Red Green Blue Yellow Magenta Cyan Opacity Opaque Semi-Transparent Text Background Color Black White Red Green Blue Yellow Magenta Cyan Opacity Opaque Semi-Transparent Transparent Caption Area Background Color Black White Red Green Blue Yellow Magenta Cyan Opacity Transparent Semi-Transparent Opaque Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Drop shadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps Reset restore all settings to the default values Done Close Modal Dialog End of dialog window. Meanwhile, Premji Invest's affiliate PI Opportunities AIF V, Capital group, Societe Generale, Luxembourg-based Eastbridge Group and Abakkus Asset Manager cumulatively bought 1.06 crore shares or 4.42 per cent stake in Indegene for Rs 627 crore. The shares were picked up in the price range of Rs 591-591.48 apiece, taking the aggregate deal value to Rs 626.85 crore. Live Events Details of the other buyers of Indegene's shares could not be ascertained on the National Stock Exchange (NSE). Shares of Indegene declined 4.07 per cent to close at Rs 594.50 per piece on the NSE. PE firm Carlyle group's clocked an impressive 31 per cent internal rate of return over a four-year period. This highly profitable divestment marks a pivotal moment, underscoring the immense potential of India's digital healthcare sector. In April 2021, Carlyle invested USD 122 million (Rs 917 crore) in Indegene by acquiring 45.5 million shares at Rs 201 each on the stock exchanges. Carlyle executed a phased exit as Indegene scaled its global operations and went public in May 2024. The shares were sold by the PE firm at Rs 452 apiece during the initial public offering, at Rs 618 per share in December 2024, and the final tranche at about Rs 591 each in June 2025, enabling Carlyle to secure significant returns amidst varying market conditions.


Indian Express
29 minutes ago
- Indian Express
A father-son legacy of Padma honors and pioneering scientific research
Written by Siddhi Patil, Dr Chetan Eknath Chitnis, a globally renowned Indian scientist, has dedicated his life to combating malaria, a persistent global health challenge claiming countless lives annually. His groundbreaking work in malaria vaccine development has earned him the prestigious Padma Shri this year, alongside awards like the Shanti Swarup Bhatnagar Award and the Infosys Prize. Remarkably, Dr. Chitnis shares a rare distinction with his father, Eknath Vasant Chitnis, a Padma Bhushan recipient (1985) and a founding member of the Indian Space Research Organisation (ISRO). This rare father-son duo's Padma honors reflect a deep family legacy of scientific excellence, with both making transformative contributions to their respective fields. Dr. Chitnis's journey in medical research is deeply rooted in his upbringing. His father, a distinguished space scientist and former director of ISRO's Space Application Centre, instilled a passion for dedicated work. 'My father taught me that true commitment means loving what you do, no matter the hours,' Dr. Chitnis recalls. While he initially pursued physics, inspired by his father's rigor, it was his mother, a biochemist focused on cancer research, who steered him toward biology. This pivot led him to lead the Malaria Parasite Biology and Vaccines Unit at Institut Pasteur in Paris, where he drives innovative vaccine research to curb malaria's devastating impact. Pune holds a special place in Dr. Chitnis's heart. Childhood summers spent at his grandparents' home in Deccan Gymkhana, exploring nearby hills with cousins, evoke memories of a serene, green Pune. His parents' decision to settle in the city post-retirement deepened his connection. Today, as Pune evolves into a bustling hub of innovation, Dr. Chitnis is eager to engage with its academic and research communities, blending personal nostalgia with professional aspirations. From IIT Bombay to UC Berkeley, the National Institutes of Health, and the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Delhi, Dr. Chitnis's career spans continents. His work at ICGEB, supported by robust government backing, laid the foundation for his current efforts in Paris. A significant breakthrough came during the COVID-19 pandemic when delayed vaccine trials at Oxford revealed that a 14-month gap between doses reduced malaria parasite growth—an unexpected finding inspired by similar COVID-19 vaccine insights. This discovery, coupled with advancements in mRNA technology, fuels his cautious optimism for future malaria solutions. The Padma Shri holds deep significance for Dr. Chitnis. 'Being recognised by my homeland, even after a decade abroad, is humbling,' he says. He views the award as a tribute to his team's collective efforts and a call to continue serving society.